Skip to content
ChickenStockChickenStock
ResearchKURA
Kura Oncology logo

Kura Oncology (KURA) stock

NASDAQ

$7.49+5.57%(+0.39)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-2.35x

Net loss — not comparable

P/B

38.22x

P/S

8.71x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 9.5% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 10, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

19 SEC filings
  • WILSON TROY EDWARDPresident and CEO · Nov 16, 2026Open-market purchase202,238 shares · $1.5M
    Avg. price $7.42
    Show 2 price lots
    • 101,119 shares × $7.42$750K
    • 101,119 shares × $7.42$750K
  • WILSON TROY EDWARDPresident and CEO · Nov 13, 2026Open-market purchase197,762 shares · $1.5M
    Avg. price $7.63
    Show 2 price lots
    • 98,881 shares × $7.63$754K
    • 98,881 shares × $7.63$754K
  • Leoni MollieChief Medical Officer · Sep 29, 2026Open-market sale28,802 shares · $310K
    Avg. price $10.7481141,095 shares held after
  • Powl Brian T.Chief Commercial Officer · Sep 29, 2026Open-market sale15,430 shares · $166K
    Avg. price $10.7487136,819 shares held after
  • FORD KATHLEENChief Operating Officer · Sep 29, 2026Open-market sale3,668 shares · $39K
    Avg. price $10.7516142,986 shares held after
  • Leoni MollieChief Medical Officer · Sep 28, 2026Open-market sale12,448 shares · $131K
    Avg. price $10.4973169,897 shares held after
  • Powl Brian T.Chief Commercial Officer · Sep 28, 2026Open-market sale17,020 shares · $179K
    Avg. price $10.5278
    Show 2 price lots
    • 9,020 shares × $10.4973$95K
    • 8,000 shares × $10.5622$84K
  • Bair Teresa BrophyChief Legal Officer · Sep 28, 2026Open-market sale8,442 shares · $89K
    Avg. price $10.4973187,002 shares held after
  • FORD KATHLEENChief Operating Officer · Sep 28, 2026Open-market sale6,906 shares · $72K
    Avg. price $10.4973146,654 shares held after
  • DOYLE THOMAS JAMESSVP, Finance & Accounting · Sep 28, 2026Open-market sale4,607 shares · $48K
    Avg. price $10.4972142,428 shares held after
  • Burrows FrancisChief Scientific Officer · Sep 24, 2026Open-market sale20,726 shares · $225K
    Avg. price $10.832542,327 shares held after
  • Burrows FrancisChief Scientific Officer · Sep 24, 2026Option exercise30,000 shares · $185K
    Avg. price $6.1563,053 shares held after
  • WILSON TROY EDWARDPresident and CEO · Aug 24, 2026Open-market purchase100,000 shares · $1.2M
    Avg. price $12.39479,194 shares held after
  • Powl Brian T.Chief Commercial Officer · Aug 21, 2026Open-market sale4,345 shares · $52K
    Avg. price $11.8903169,269 shares held after
  • Bair Teresa BrophyChief Legal Officer · Aug 19, 2026Open-market sale31,487 shares · $398K
    Avg. price $12.63195,444 shares held after
  • WILSON TROY EDWARDPresident and CEO · Aug 17, 2026Open-market purchase100,000 shares · $1.1M
    Avg. price $11.12379,194 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Kura Oncology (KURA) stock information

NASDAQ

Kura Oncology (KURA) is listed on NASDAQ. Its market capitalization is about $688M. On trailing-twelve-month earnings the P/E ratio is -2.35, and the P/B ratio is 38.22. Return on equity is -1627.8%. These figures are computed in-house from official filings and are reference information only.

Kura Oncology — frequently asked questions

What is the P/E ratio of Kura Oncology (KURA)?
On a trailing-twelve-month basis, KURA trades at a P/E ratio of -2.35. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Kura Oncology?
KURA has a market capitalization of about $688M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.